ARTICLE | Clinical News

Elinogrel: Phase II data

September 6, 2010 7:00 AM UTC

In the double-blind, international Phase II INNOVATE-PCI trial in about 650 patients undergoing non-urgent PCI, 100 and 150 mg doses of elinogrel produced a significantly faster and greater anti-platelet effect than loading doses of Plavix clopidogrel within 15-30 minutes (p=0.015 and p=0.007, respectively) and at 20 hours after administration (p=0.025 and p=0.016, respectively). Portola said the trial was not designed or powered to examine a specific primary endpoint. Elinogrel was well tolerated with no significant increases in the risk of thrombolysis in myocardial infarction (TIMI) major and minor bleeding. ...